About NGIVD
NGIVD is a company based in Gurugram (India) founded in 2015 by Ashok Jain, Srinivas Aluri Rao, Rajan T V, Pravin Kini, and Vivek Chandra. NGIVD has raised $1.85 million across 4 funding rounds from investors including Dipalee Ameet Desai, Aluri Rao Srinivasa and Rajan Viswanathan. NGIVD operates in a competitive market with competitors including ArcherDX, Qiagen, Devyser, DxTerity and PredictImmune, among others.
- Headquarter Gurugram, India
- Founders Ashok Jain, Srinivas Aluri Rao, Rajan T V, Pravin Kini, Vivek Chandra
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nextgen In-Vitro Diagnostics Private Limited
- Date of Incorporation 24 Apr, 2015
- Jurisdiction New Delhi, Delhi, India
-
Annual Revenue
$132.42 K (USD)135.86as on Mar 31, 2023
-
Net Profit
-$444.52 K (USD)-29.86as on Mar 31, 2023
-
EBITDA
-$467.15 K (USD)-18.26as on Mar 31, 2023
-
Total Equity Funding
$1.85 M (USD)
in 4 rounds
-
Latest Funding Round
$498.53 K (USD), Angel Round
Nov 11, 2020
-
Investors
& 11 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of NGIVD
Unlock access to complete
Unlock access to complete
Funding Insights of NGIVD
NGIVD has successfully raised a total of $1.85M across 4 strategic funding rounds. The most recent funding activity was a Angel Round of $498.53 thousand completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NGIVD
NGIVD has secured backing from 12 investors, including angel investors. Prominent investors backing the company include Dipalee Ameet Desai, Aluri Rao Srinivasa and Rajan Viswanathan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
DA
Dipalee Ameet Desai |
-
|
Locked | Locked | Locked |
|
AR
Aluri Rao Srinivasa |
-
|
Locked | Locked | Locked |
|
RV
Rajan Viswanathan |
-
|
Locked | Locked | Locked |
Investor details for NGIVD
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NGIVD
Investment portfolio details for NGIVD
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NGIVD
Detailed financials for NGIVD
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ngivd Comparisons
Peer comparison for NGIVD
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NGIVD
NGIVD operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ArcherDX, Qiagen, Devyser, DxTerity and PredictImmune, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Products and reagents for molecular diagnostic assays are supplied.
|
|
| Locked | Locked | Locked |
Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders
|
|
| Locked | Locked | Locked |
Provider of a direct-to-consumer, non-clinical genetic tests
|
|
| Locked | Locked | Locked |
Tools for diagnosing immune-mediated inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Manufacturer of specialist molecular biology analytical instruments and reagents
|
Detailed competitors of NGIVD
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ngivd
Complete news archive for NGIVD
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NGIVD
NGIVD was founded in 2015 and raised its 1st funding round 2 years after it was founded.
NGIVD is headquartered in Gurugram, India. It is registered at Gurugram, Haryana, India.
Vivek Chandra is the current CEO of NGIVD. They have also founded this company.
NGIVD is a funded company, having raised a total of $1.85M across 4 funding rounds to date.
Annual revenue of NGIVD is $132.42K as on Mar 31, 2023.
NGIVD was founded in 2015 and is headquartered in Gurugram, India. In-vitro diagnostic solutions targeting infectious diseases are developed by the company within the healthcare sector. Products such as rapid card tests, ELISA kits, clinical chemistry kits, RT-PCR kits, nucleic acid purification kits, and reagents are provided for research and diagnostic applications. Operations emphasize tools for disease detection and analysis in laboratory settings.
NGIVD has 12 investors. Key investors include Dipalee Ameet Desai, Aluri Rao Srinivasa, Rajan Viswanathan, K Sridharan, and Bharati Gupta.